Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Chief Executive Officer of Blue Earth Diagnostics. from October 1 to 4, 2023. “PET Gauden , D.Phil.,

Diagnostic 93

Diagnostic Radiation Oncology Radiation Clinic 93

Imaging Technology

OCTOBER 5, 2023

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Gauden, D.Phil.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

Imaging Technology

JULY 28, 2023

POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,

Clinic 84

Clinic Diagnostic Radiopharmaceuticals Radiation 84

AuntMinnie

JUNE 20, 2024

Medical imaging is used to localize parathyroid adenomas in patients with PHPT, a condition often diagnosed based on high calcium levels. To establish which of the two is the optimal first-line approach, the group enrolled 57 patients (63 years old on average; 15 men and 42 women) in a multicenter randomized diagnostic intervention trial.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Imaging Clinic 105

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 75

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 75

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

MAY 14, 2024

Siemens Healthineers and UH will look to also advance the treatment of patients with Alzheimer’s disease and use theranostics—combining the approaches of diagnostics and therapeutics—to treat patients with advanced forms of certain cancers, as well as develop new magnetic resonance ( MR ) technologies.

Hospital 103

Hospital Magnetic Resonance Imaging Radiopharmaceuticals Disease 103